Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
Juliann Chmielecki(Memorial Sloan Kettering Cancer Center), William Pao(Albany Medical Center Hospital), Michelle S. Ginsberg(Memorial Sloan Kettering Cancer Center), Romel Somwar(Memorial Sloan Kettering Cancer Center), Jasmine Foo(Dana-Farber Cancer Institute), Akira Inoue(Tohoku University Hospital), Mark G. Kris(Memorial Sloan Kettering Cancer Center), Geoffrey R. Oxnard(Foundation Medicine (United States)), Katherine Amato(Vanderbilt University), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), Nicholas D. Socci, Maria E. Arcila(Memorial Sloan Kettering Cancer Center), Martin L. Sos(German Cancer Research Center), Roman K. Thomas(University of Cologne), Agnès Viale(Genomics (United Kingdom)), Katherine E. Hutchinson(Vanderbilt University), Franziska Michor(Dana-Farber Cancer Institute), Lu Wang(The Central Hospital of Xiao gan), Kadoaki Ohashi(Okayama University Hospital), Vincent A. Miller(Universidad San Carlos), Elisa de Stanchina(Memorial Sloan Kettering Cancer Center)
Cited by 530
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k